M Platten

Summary

Affiliation: University of Heidelberg
Country: Germany

Publications

  1. pmc Promotion of glioblastoma cell motility by enhancer of zeste homolog 2 (EZH2) is mediated by AXL receptor kinase
    Martina Ott
    Department of Neurooncology, University Hospital Heidelberg, Heidelberg, Germany
    PLoS ONE 7:e47663. 2012
  2. doi request reprint Microenvironmental clues for glioma immunotherapy
    Michael Platten
    Department of Neurooncology, University Hospital Heidelberg and National Center for Tumor Diseases, German Cancer Consortium DKTK Clinical Cooperation Units, Im Neuenheimer Feld, Heidelberg, Germany
    Curr Neurol Neurosci Rep 14:440. 2014
  3. ncbi request reprint [Clinically isolated syndrome]
    M Platten
    Abteilung Neuroonkologie, Neurologische Klinik, Universitatsklinikum Heidelberg, INF 400, 69120, Heidelberg, Deutschland
    Nervenarzt 84:1247-59. 2013
  4. doi request reprint Tryptophan catabolism in cancer: beyond IDO and tryptophan depletion
    Michael Platten
    Department of Neurooncology, University Hospital Heidelberg, German Cancer Research Center DKFZ, Heidelberg, Germany
    Cancer Res 72:5435-40. 2012
  5. ncbi request reprint [Personalized neurooncology]
    M Platten
    Abteilung Neuroonkologie, Neurologische Klinik und Nationales Zentrum für Tumorerkrankungen, Universitatsklinikum Heidelberg, INF 400, 69120, Heidelberg, Deutschland
    Nervenarzt 84:937-42. 2013
  6. doi request reprint [Treatment of brain tumor patients: hyperthermia, hyperbaric oxygenation, electric fields or nanoparticles]
    M Platten
    Abteilung Neuroonkologie, Universitatsklinikum Heidelberg, INF 400, 69120 Heidelberg, Deutschland
    Nervenarzt 83:982-7. 2012
  7. ncbi request reprint Painful neuropathy due to intraneural leukemic spread in a patient with acute myeloid leukemia
    M Platten
    Department of Neurooncology, University Hospital of Heidelberg, Heidelberg, Germany
    Neurology 69:707. 2007
  8. pmc Does age matter? - A MRI study on peritumoral edema in newly diagnosed primary glioblastoma
    Clemens Seidel
    Department of Neurooncology University Clinic Heidelberg, Germany
    BMC Cancer 11:127. 2011
  9. doi request reprint [Neuroradiological response criteria for malignant gliomas]
    M Bendszus
    Abteilung Neuroonkologie, Universitatsklinikum Heidelberg, Im Neuenheimer Feld 400, 69120, Heidelberg, Deutschland
    Nervenarzt 81:950-5. 2010
  10. ncbi request reprint Suppression of proinvasive RGS4 by mTOR inhibition optimizes glioma treatment
    M Weiler
    Clinical Cooperation Unit Neurooncology, German Cancer Research Center DKFZ, Heidelberg, Germany
    Oncogene 32:1099-109. 2013

Collaborators

Detail Information

Publications13

  1. pmc Promotion of glioblastoma cell motility by enhancer of zeste homolog 2 (EZH2) is mediated by AXL receptor kinase
    Martina Ott
    Department of Neurooncology, University Hospital Heidelberg, Heidelberg, Germany
    PLoS ONE 7:e47663. 2012
    ..Finally, AXL expression is found in human gliomas with high EZH2 expression. Collectively these data suggest that EZH2 drives glioma invasiveness via transcriptional control of AXL independent of histone or DNA methylation...
  2. doi request reprint Microenvironmental clues for glioma immunotherapy
    Michael Platten
    Department of Neurooncology, University Hospital Heidelberg and National Center for Tumor Diseases, German Cancer Consortium DKTK Clinical Cooperation Units, Im Neuenheimer Feld, Heidelberg, Germany
    Curr Neurol Neurosci Rep 14:440. 2014
    ..Here we review the current clinical and preclinical evidence of antimicroenvironment immunotherapeutic strategies in gliomas. ..
  3. ncbi request reprint [Clinically isolated syndrome]
    M Platten
    Abteilung Neuroonkologie, Neurologische Klinik, Universitatsklinikum Heidelberg, INF 400, 69120, Heidelberg, Deutschland
    Nervenarzt 84:1247-59. 2013
    ..Additionally, recommendations are given regarding the management of radiologically isolated syndrome (RIS) an imaging-based diagnosis of a potential preclinical stage of MS. ..
  4. doi request reprint Tryptophan catabolism in cancer: beyond IDO and tryptophan depletion
    Michael Platten
    Department of Neurooncology, University Hospital Heidelberg, German Cancer Research Center DKFZ, Heidelberg, Germany
    Cancer Res 72:5435-40. 2012
    ..This review summarizes the exciting developments in our understanding of tryptophan catabolism as a key factor in the immunobiology of cancer...
  5. ncbi request reprint [Personalized neurooncology]
    M Platten
    Abteilung Neuroonkologie, Neurologische Klinik und Nationales Zentrum für Tumorerkrankungen, Universitatsklinikum Heidelberg, INF 400, 69120, Heidelberg, Deutschland
    Nervenarzt 84:937-42. 2013
    ..This article illustrates the current developments in the area of personalized neurooncology and critically reviews the impact on clinical decision-making in daily practice. ..
  6. doi request reprint [Treatment of brain tumor patients: hyperthermia, hyperbaric oxygenation, electric fields or nanoparticles]
    M Platten
    Abteilung Neuroonkologie, Universitatsklinikum Heidelberg, INF 400, 69120 Heidelberg, Deutschland
    Nervenarzt 83:982-7. 2012
    ..In this review we review these clinical therapeutic approaches...
  7. ncbi request reprint Painful neuropathy due to intraneural leukemic spread in a patient with acute myeloid leukemia
    M Platten
    Department of Neurooncology, University Hospital of Heidelberg, Heidelberg, Germany
    Neurology 69:707. 2007
  8. pmc Does age matter? - A MRI study on peritumoral edema in newly diagnosed primary glioblastoma
    Clemens Seidel
    Department of Neurooncology University Clinic Heidelberg, Germany
    BMC Cancer 11:127. 2011
    ..As older age is a negative prognostic marker and as VEGF expression is reported to be increased in primary glioblastoma of older patients, age-related differences in the extent of peritumoral edema have been assessed...
  9. doi request reprint [Neuroradiological response criteria for malignant gliomas]
    M Bendszus
    Abteilung Neuroonkologie, Universitatsklinikum Heidelberg, Im Neuenheimer Feld 400, 69120, Heidelberg, Deutschland
    Nervenarzt 81:950-5. 2010
    ..Thus both neuroradiologists and neurologists/neurooncologists need to be aware of and experienced in applying these criteria when treating patients with malignant gliomas to be able to correctly assess the response to therapy...
  10. ncbi request reprint Suppression of proinvasive RGS4 by mTOR inhibition optimizes glioma treatment
    M Weiler
    Clinical Cooperation Unit Neurooncology, German Cancer Research Center DKFZ, Heidelberg, Germany
    Oncogene 32:1099-109. 2013
    ..We conclude that combined RT and mTOR inhibition is a promising therapeutic option that warrants further clinical investigation in upfront glioblastoma therapy...
  11. ncbi request reprint Tryptophan degradation in autoimmune diseases
    C A Opitz
    Department of Neurooncology, University Hospital of Heidelberg, Germany
    Cell Mol Life Sci 64:2542-63. 2007
    ..Possible therapeutic approaches for autoimmune disorders targeting Trp degradation are presented, and key issues relevant for the development of such therapeutic strategies are discussed...
  12. doi request reprint NDRG1 prognosticates the natural course of disease in WHO grade II glioma
    J Blaes
    German Cancer Consortium DKTK, Clinical Cooperation Units Neurooncology, German Cancer Research Center DKFZ, Heidelberg, Germany
    J Neurooncol 117:25-32. 2014
    ..Validation of this hypothesis will be possible with the observational arm of the RTOG 9802 and the pretreatment step of the EORTC 22033/26032 trials...
  13. ncbi request reprint Primary cerebral non-Langerhans cell histiocytosis: MRI and differential diagnosis
    U Ernemann
    Department of Neuroradiology, University Hospital Tubingen, Hoppe Seyler Strasse 3, 72076 Tubingen, German
    Neuroradiology 44:759-63. 2002
    ..Whereas the cutaneous form of juvenile xanthogranuloma is usually benign and self-limited, central nervous system involvement is associated with high morbidity and mortality and might therefore be considered a separate clinical entity...